Shows
tHEORetically SpeakingWeekly News Roundup — Regulatory RWE Battles, Capital Market Moves, and Cash-Pay Drug Pricing DisruptionThis week's tHEORetically Speaking News Roundup covers Humana’s rollout of a Google Cloud–powered AI tool to streamline 80 million annual member calls, Amgen’s pushback against the FDA to keep Tavneos on the market using real-world evidence, and AstraZeneca’s NYSE debut to fuel its global growth strategy. We also explore the new TrumpRx portal aimed at expanding discounted cash-pay prescriptions. Tune in for this concise recap of these pivotal industry updates! Register for World EPA Congress 2026 here:https://www.terrapinn.com/EPA/2026/HealthEconomics
2026-02-0604 min
tHEORetically SpeakingINsights & OUTcomes with Taylor HirschbergThis episode features Taylor Hirschberg, an award winning writer, activist, and academic. He is the CEO of Metli Consulting, an inclusive consultancy firm focused on helping to prepare for launch and providing a faster, more flexible approach to market access.Learn more about Metli Consulting: https://www.metliconsulting.com/“Science without story fails to reach policymakers. Policy without equity fails communities. Story without evidence fails everyone. Metli is a life sciences and public health consulting firm founded at the intersection of science, policy, communications, and human impact.”Health Economics is moving fast. From valu...
2026-02-0228 min
tHEORetically SpeakingWeekly News Roundup — Rare Disease Funding Risks, Medicare Advantage Reform, and Global Trade ShiftsThis week’s tHEORetically Speaking News Roundup covers the looming funding crisis for rare disease biotechs as FDA priority review vouchers expire, CMS’s proposed crackdown on Medicare Advantage upcoding, and Cellares’ $257 million raise to scale automated cell therapy manufacturing. We also explore Sanofi’s defense of vaccines amid shifting U.S. policy and a landmark EU–India free trade agreement set to reshape global pharma access. Tune in for a concise recap of these pivotal industry updates!
2026-01-3004 min
tHEORetically SpeakingWeekly News Roundup — Oral GLP-1 Momentum, Trade Tensions, EU Drug Security, and AI Risk WarningsThis week’s tHEORetically Speaking News Roundup covers Novo Nordisk’s early momentum with oral Wegovy amid intensifying GLP-1 competition, rising geopolitical trade tensions threatening pharma market access, and Europe’s push to secure medicine supply chains through the Critical Medicines Act. We also examine new warnings on the misuse of medical AI heading into 2026. Tune in for this concise recap of the week’s most impactful HEOR, RWE, and market access developments.
2026-01-2303 min
tHEORetically SpeakingWeekly News Roundup — Neurodegeneration Deals, Generative AI, and Drug Pricing PoliticsThis week’s tHEORetically Speaking News Roundup covers Novartis’ $1.5B Alzheimer’s licensing deal, the FDA’s push to accelerate drug development through Bayesian trial methods, and Bayer’s move to scale generative AI in antibody discovery. We also break down Oxford Biomedica’s takeover talks and a newly unveiled US healthcare cost plan.Tune in for a concise recap of these pivotal industry updates!
2026-01-1603 min
tHEORetically SpeakingWeekly News Roundup — Oncology Shakeups, FDA Wellness Crackdown, and AI-Powered Drug DiscoveryThis week’s tHEORetically Speaking News Roundup covers GSK’s abrupt exit from its five-year synthetic lethality partnership with Ideaya, Whoop’s escalating regulatory clash with the FDA over its unapproved blood-pressure feature, and new evidence showing how minimum wage and EITC policies improve maternal mental health. We also break down Medra’s $52M raise and its new AI-driven drug-discovery partnership with Genentech. Tune in for this concise recap of these pivotal industry updates!
2025-12-1203 min
tHEORetically SpeakingWeekly News Roundup — Tariff-Free Pharma, Biologics Modernization, Duchenne Trial Success, and Maternal Health AdvancesThis week’s tHEORetically Speaking News Roundup breaks down four major developments shaping policy and biopharma. We cover the new US–UK trade deal exempting pharma from tariffs and resetting NHS pricing, the FDA’s push to curb non-human primate testing for monoclonal antibodies, and Capricor’s breakthrough Phase 3 results in Duchenne muscular dystrophy. We also highlight new HEOR research using copula modeling to better understand drivers of low birth weight and preterm birth. Tune in for a fast, 4-minute briefing on the most important shifts across science, regulation, and market access.
2025-12-0503 min
tHEORetically SpeakingWeekly News Roundup — Premium Hikes, Predictive AI Breakthroughs, and Public Health Policy FalloutThis week’s tHEORetically Speaking News Roundup covers Medicare’s 10% Part B premium hike for 2026 and its potential to push more seniors toward Medicare Advantage, Clairity’s $43M raise to expand its FDA-cleared predictive AI platform beyond mammography, and the RISE Committee’s controversial move to exclude public health degrees from its professional program definition.Tune in for this concise recap of these pivotal policy, innovation, and workforce updates!
2025-11-2103 min
tHEORetically SpeakingWeekly News Roundup — Four Big Moves in Medtech, Neurotech, Biopharma R&D & Pharma M&AThis week on tHEORetically Speaking, we’re covering four major stories shaping the landscape across medtech, neurotech, drug development, and global pharma: Laborie buys Organon’s Jada system, NextSense raises a new round to launch EEG Smartbuds, Evotec and BMS hit an IND milestone, and Merck goes big with a $9.2B antiviral acquisition. A fast, focused roundup of the headlines you need to know. Subscribe for weekly drops!
2025-11-1402 min
tHEORetically SpeakingWeekly News Roundup – FDA Shakeups, Novo Nordisk’s Strategic Reset, and Smart Data for Diabetes InnovationThis week’s tHEORetically Speaking News Roundup covers the sudden resignation of the FDA’s top drug chief amid controversy, Novo Nordisk’s sweeping restructuring and strategic reset in the obesity and diabetes markets, and a groundbreaking data partnership between ŌURA and Tidepool driving innovation in diabetes research. We also explore how rising healthcare costs threaten the future of clinical trial diversity. Tune in for this concise recap of these pivotal industry updates!
2025-11-0704 min
tHEORetically SpeakingWeekly News Roundup – Neuro Breakthroughs, Biosimilar Reform, and an Obesity Drug ShowdownThis week’s tHEORetically Speaking News Roundup covers Evotec and Bristol Myers Squibb’s progress in developing next-generation therapies for neurodegenerative diseases, the FDA’s game-changing move to streamline biosimilar approvals and lower drug costs, and Novo Nordisk’s bold $6.5B counteroffer to outbid Pfizer for Metsera in the obesity treatment race.Tune in for this concise recap of the top stories shaping HEOR, RWE, and Market Access this week.
2025-10-3103 min
tHEORetically SpeakingWeekly News Roundup – Real-World Wins and Billion-Dollar BreakthroughsThis week’s tHEORetically Speaking News Roundup covers Astellas Pharma’s Phase 4 findings showing fezolinetant’s real-world benefits for menopausal symptom relief, improved sleep, and daily functioning. We also dive into Takeda’s $11 billion collaboration with Innovent Biologics to advance next-generation cancer therapies and expand its global oncology pipeline.Tune in for this concise recap of these pivotal industry updates!
2025-10-2403 min
tHEORetically SpeakingINsights & OUTcomes with Dalfoni BanerjeeThis episode features Dalfoni Banerjee, an award-winning entrepreneur and consultant with over 30 years of hands-on experience and her expertise spans the full drug development cycle. In 2011, Dalfoni founded and continues to operate 3Sixty Pharma Solutions, which has a mission to support startup and established pharmaceutical, biotechnology, and medical device companies with subject matter experts who help teams accelerate development, overcome challenges, and avoid preventable delays.Learn more about 3Sixty Pharma Solutions here: https://3sixtypharma.com/Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to miss what's n...
2025-10-2118 min
tHEORetically SpeakingWeekly News Roundup – CAR-T Safety Alerts, Policy Ripple Effects, and Notable WearablesThis week’s tHEORetically Speaking News Roundup covers the FDA’s new boxed warning for J&J’s CAR-T therapy Carvykti, a major study linking post-Dobbs abortion restrictions to rising intimate partner violence, and Pelage Pharmaceuticals’ $120M funding to advance a next-generation hair loss treatment. We also spotlight Ōura’s $900M investment to expand its AI-driven health tech platform. Tune in for this concise recap of these pivotal industry updates!
2025-10-1703 min
MAP - Market Access PodcastWill AI and Living Reviews Define the Next Era of Health Policy, Anna Forsythe?Join this episode of MAP – The Market Access Podcast as Dr. Stefan Walzer sits down with Anna Forsythe, founder of OncoScope-AI, to explore how Living Systematic Literature Reviews (Living SLRs) are redefining evidence generation in oncology and beyond - highlighting the power of real-time updates, advanced automation, and the essential role of human insight.Traditional SLRs are static snapshots, while Living SLRs are real-time, dynamic, and AI-powered—delivering continuously updated insights crucial for life-or-death decisions and payer evaluations. Join this discussion as they explore the myth of AI chatbots as true decision support tools, the need for acti...
2025-10-1529 min
tHEORetically SpeakingWeekly News Roundup – Immunology, Innovation, and ImpactThis week’s tHEORetically Speaking News Roundup covers nirsevimab’s real-world success in reducing RSV hospitalizations among infants, Boehringer Ingelheim’s FDA approval of Jascayd for idiopathic pulmonary fibrosis, and Arthrosi Therapeutics’ $153 million raise to advance a next-generation gout drug. We also highlight this year’s Nobel Prize in Medicine, honoring discoveries in immune tolerance that continue to shape today’s biggest breakthroughs.Tune in for this concise recap of these pivotal industry updates!
2025-10-1003 min
tHEORetically SpeakingtHEORetically Speaking: Rethinking Decentralization in Direct-to-Patient StudiesIn this episode of tHEORetically Speaking, Paige McGarry interviews Aaron Berger, SVP & Head of Evidence Development Solutions at UBC discussing the evolution of direct-to-patient (DTP) study designs and how they are reshaping the landscape of clinical research.Learn more here: https://healtheconomics.com/theoretically-speaking-rethinking-decentralization-in-direct-to-patient-studies/Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to miss what's next. Join thousands of professionals who trust Health Economics.com as their go to resource. Subscribe for weekly insights, expert commentary, and the latest developments across HEOR...
2025-10-0614 min
tHEORetically SpeakingWeekly News Roundup – Medicaid Deals, Oncology Innovation, and Market Tensions AbroadThis week’s tHEORetically Speaking News Roundup covers Pfizer’s new Medicaid pricing deal with the current administration, Cartography Biosciences’ $67M raise to advance its next-generation colorectal cancer therapy, and calls for a U.K. anticompetition probe into pharma investment freezes.Tune in for this concise recap of the key HEOR, RWE, and Market Access headlines shaping our industry.
2025-10-0303 min
MAP - Market Access PodcastAre We Undervaluing the Economic Power of Health, Dr. Malina Müller?In the latest MAP Podcast, our host Dr. Stefan Walzer is joined by Dr. Malina Müller from the WifOR Institute to rethink how we value health. From real-world ROI data to policy shifts and long-term strategies, they explore why investing in health pays off—not just in lives saved, but in economic growth, workforce productivity, and resilient societies.Listen now to discover how viewing healthcare as an investment—not just a cost—can transform market access and what it means for pricing, innovation, and the future of care. If you work in pharma, policy, or health economi...
2025-10-0138 min
tHEORetically SpeakingINsights & OUTcomes with Renée ArnoldThis episode features Dr. Renée Arnold, the President & CEO of Arnold Consultancy & Technology, LLC (ACT), focusing on outcomes research and software for healthcare sectors. She specializes in evidence-based health and real-world data modeling for healthcare decisions. Dr. Arnold is a founding member of ISPOR and chairs a special interest group at the Society for Medical Decision Making, with numerous publications in her field.Learn more about some of Renée's work here: https://healtheconomics.com/modex-revolutionizing-cancer-drug-pricing-and-access-through-open-source-health-economic-models/Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to mi...
2025-09-3026 min
tHEORetically SpeakingWeekly News Roundup – Public Health Flashpoints, Pharma Innovation, and Pricing BattlesThis week’s tHEORetically Speaking News Roundup covers the ACIP’s heated vaccine policy debates, growing state-level divides in COVID-19 vaccine access, and pharma’s race to develop multi-specific antibodies. We also explore the looming $32 billion revenue loss tied to expiring ACA subsidies and the latest legal battles over IRA drug pricing.Tune in for this concise recap of these pivotal industry updates!
2025-09-2605 min
tHEORetically SpeakingWeekly News Roundup – Vaccine Policy Shifts, AI-Powered R&D, and Billion-Dollar InvestmentsThis week’s tHEORetically Speaking News Roundup covers the CDC’s ACIP meeting and its implications for U.S. vaccine policy, GHO Capital’s acquisition of AI-powered R&D platform Scientist.com, and GSK’s $30 billion investment in U.S. drug manufacturing. We also explore Eli Lilly’s promising pediatric trial results for Mounjaro in type 2 diabetes and several upcoming FDA decisions poised to reshape the pharmaceutical landscape.Tune in for this concise recap of these pivotal industry updates!
2025-09-1904 min
MAP - Market Access PodcastHow Should Pharma Respond to the New Reality of Market Access in Germany, Prof. Dr. Thomas Hammerschmidt?In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with expert Prof. Dr. Thomas Hammerschmidt, to dive deep into Germany’s evolving AMNOG framework and what it really means for pharmaceutical pricing. This insightful conversation explores key changes in Germany’s pharma landscape, including the shift from negotiation-based pricing to benefit-linked guardrails, the 5% clinical trial rule, and their impact on innovation and reimbursement strategy. A must-listen for pharma professionals, health economists, and market access leaders!Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected throu...
2025-09-1534 min
tHEORetically SpeakingWeekly News Roundup – Pharma Acquisitions, Trial Triumphs, and Coding ControversiesThis week’s tHEORetically Speaking News Roundup covers new research on social-genetic influences in adolescent depression, Novartis’s $1.4B acquisition of Tourmaline Bio for a promising heart drug, and encouraging Phase 2 results for rezatapopt in solid tumors. We also explore the FDA’s draft guidance on non-opioid pain treatments and the AMA’s release of 2026 CPT codes amid growing scrutiny.Tune in for this concise recap of these pivotal industry updates!
2025-09-1204 min
tHEORetically SpeakingWeekly News Roundup – Obesity Drug Rivalry, Rare Disease Pathways, Vaccine Mandate Battles, and ACA Shake-UpsThis week’s tHEORetically Speaking News Roundup covers Novo’s Wegovy showing superior cardiovascular benefits over Lilly’s Zepbound, the FDA’s new Rare Disease Evidence Principles to accelerate ultra-rare drug development, and Florida’s move to abolish vaccine mandates. We also explore HHS’s expansion of catastrophic health plans amid looming ACA premium hikes. Tune in for this concise recap of these pivotal industry updates!
2025-09-0504 min
MAP - Market Access PodcastDo Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?Tune in to this episode of MAP – The Market Access Podcast, to hear from Dr. Stefan Walzer as he speaks with Swiss reimbursement expert Petra Erni, who brings a rare perspective from both the industry and payer sides.Together they explore the evolving Swiss drug reimbursement landscape, discussing the rise of cost consequence models, the growing role of health economic evidence, early access pathways, and strategic pricing challenges in Switzerland. Essential listening for pharma, market access, and health policy professionals—especially those eyeing the Swiss market.Stay updated for upcoming webinars through LinkedIn, and take the...
2025-09-0129 min
tHEORetically SpeakingWeekly News Roundup – Ransomware Shocks, Vaccine Policy Shifts, and Billion-Dollar Pharma InvestmentsThis week’s tHEORetically Speaking News Roundup covers DaVita’s massive ransomware attack impacting 2.7 million patients, the FDA’s updated COVID-19 booster approvals for high-risk groups, and Roche’s $700M investment in a new obesity drug facility in North Carolina. We also highlight Virginia’s success in attracting major pharma investments from AstraZeneca and Eli Lilly. Tune in for this concise recap of the week’s most important HEOR, RWE, and Market Access updates!
2025-08-2903 min
tHEORetically SpeakingWeekly News Roundup – Alzheimer’s Breakthroughs, Cancer Trial Advances, and High-Stakes Policy BattlesThis week’s tHEORetically Speaking News Roundup covers semaglutide’s potential in Alzheimer’s treatment, Delcath’s new Phase II trial for colorectal cancer, and a court ruling overturning limits on Medicare Advantage broker payments. We also break down CVS’s $290 million penalty for Medicare drug overcharges and the Supreme Court’s decision upholding NIH grant cuts tied to DEI policies. Tune in for this concise recap of the week’s most impactful industry updates!
2025-08-2203 min
tHEORetically SpeakingWeekly News Roundup - Pharmacist Empowerment, Financial Shifts, and Innovative Health SolutionsThis week's tHEORetically Speaking News Roundup covers the impact of pharmacists prescribing minor ailments in Ontario, significant Medicaid payment cuts affecting US hospitals, and Kaiser Permanente's robust Q2 earnings amidst cost pressures. We also delve into the FDA's PreCheck program for boosting US pharma manufacturing and the approval of a groundbreaking immunotherapy for a rare respiratory disease. Tune in for this concise recap of these pivotal industry updates!
2025-08-1504 min
tHEORetically SpeakingWeekly News Roundup - Pharma Pilots, Legal Battles, and Precision Medicine BreakthroughsThis week's tHEORetically Speaking News Roundup covers the U.S. Department of Health and Human Services' new 340B rebate model pilot, a lawsuit against Novo Nordisk over misleading sales projections for Ozempic and Wegovy, and the GAO's findings on illegal NIH grant cuts by the Trump administration. We also delve into Merck's $10 billion acquisition of Verona Pharma and AstraZeneca's precision strategy in lung cancer treatment. Tune in for a concise recap of these pivotal industry updates!
2025-08-0804 min
tHEORetically SpeakingWeekly News Roundup - Vaccine Triumphs, Revolutionary Trials, and Data-Driven Health FuturesThis week's tHEORetically Speaking News Roundup covers Moderna's strides toward COVID-19 vaccine approval in Europe, Eli Lilly's promising trial results for Jaypirca in leukemia treatment, and J&J's innovative CAR-T therapy ad campaign. We also explore the Trump administration's new health data sharing initiative and a groundbreaking platform predicting antibiotic resistance. Tune in for this concise recap of these pivotal industry updates!
2025-08-0104 min
MAP - Market Access PodcastEurope vs. US: Who Leads the Future of Market Access, Dr. Doug Niven?In this thought-provoking episode of MAP, the Market Access Podcast, Dr. Stefan Walzer sits down with strategic Market Access consultant Dr. Doug Niven to explore one of the most pressing questions in pharma today - can Europe maintain its leadership in Market Access, or is it falling behind? From joint HTA (JCA), pricing reforms, and AI-driven tools to global value frameworks and real-world data, this episode unpacks key trends shaping pharma, biotech, and healthcare access in 2025 and beyond. If you're in health economics, pricing & reimbursement, or regulatory strategy, this is a must-listen.Stay updated for u...
2025-08-0143 min
tHEORetically SpeakingtHEORetically Speaking: Meeting the Resource Challenge - Why Biotechs Need a Different Kind of PartnerIn this episode of Theoretically Speaking, Paige McGarry interviews David W. Miller, CEO of Genesis Research Group, discussing the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.David W. Miller discusses how Genesis Research Group addresses these challenges, including the importance of demonstrating value early in development, the role of real-world evidence in supporting biotechs, and how to navigate uncertainty in the biotech landscape. Additionally, strategies for effective data collection are introduced, while emphasizing the need for flexibility and adaptability in the ever-evolving life sciences sector. Genesis Research Group's F...
2025-07-2828 min
177 Nations of TasmaniaIngrid from St Lucia : A touch of the Caribbean in TasmaniaIngrid hails from the tiny island nation of Saint Lucia, a lushCaribbean island known for its volcanic peaks, vibrant Creole culture, and status as the only country named after a woman. With a population of around 180,000, Saint Lucia blends African, French, and British influences, and though its official language is English, many speak Saint Lucian Creole.Ingrid trained as a physician in Cuba on a Saint Luciangovernment scholarship, worked in paediatrics, and later took on various public health roles across the Caribbean. She made a big move to study Master’s degree in Adelaide, where she met herp...
2025-07-2841 min
MAP - Market Access PodcastWhat Does It Really Take to Master AMNOG in Today’s Market Access Landscape, Anja Pownell?Tune in to this new episode of the Market Access Podcast, where our host Dr. Stefan Walzer is joined by AMNOG expert Anja Pownell to bust some of the most persistent misconceptions about German market access—and share actionable survival tips for navigating the GBA process.Learn how to strategically prepare for AMNOG submissions, navigate price negotiations, and leverage AI tools to streamline dossier writing and literature reviews. A must-listen for anyone involved in pharmaceutical pricing, reimbursement, and European market access strategy.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay co...
2025-07-1525 min
MAP - Market Access PodcastIs Cross-Functional Alignment the Secret to Successful Market Access, Kasem Akhras?In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with Kasem Akhras, veteran access strategist and author of Frontiers in Market Access, to unpack what it really takes to bring innovative therapies to patients across emerging markets. From the rising demand for innovative therapies to the tightening grip of healthcare budgets, this episode explores the real challenges and opportunities in market access today. Discover why pricing strategies must be tailored to each market, how cross-functional collaboration and early planning are key to success, and how digital health and AI are reshaping the future...
2025-07-0138 min
MAP - Market Access PodcastHow Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?Tune in to the latest episode of the Market Access Podcast, where Dr. Stefan Walzer welcomes statistician and Evimed founder Necdet Gunsoy to explore the critical role of statistics in health economics, HTA, and payer strategy. Learn how better collaboration between statisticians and market access teams can drive evidence-based decision-making, improve communication, and support strategic planning—plus the impact of AI on future workflows.This conversation spans key topics—from real-world evidence and health technology assessment (HTA) to internal cross-functional alignment and strategic planning in market access. Whether you're a health economist, market access leader, or data expe...
2025-06-1536 min
tHEORetically SpeakingINsights & OUTcomes with Matt McLoughlinThis episode features Matt McLoughlin, Senior Vice President of Compliance and Categories at Scientist.com. With 25 years in pharma R&D and Procurement, Matt has enhanced outsourcing for biopharma companies, focusing on speed, efficiency, and compliance. His expertise in regulated industries extends to RWE, HEOR, and Market Access, transforming access to external services to boost innovation while cutting costs and project timelines.To stay connected with us, visit our LinkedIn page and subscribe to our newsletter!Learn more about Scientist.com and how they can help with planning your book of work here...
2025-06-1022 min
tHEORetically SpeakingINsights & OUTcomes with Catherine BaconWelcome to INsights & OUTcomes, the newest podcast on tHEORetically Speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.This episode features Catherine Bacon, founder of FingerPost Consulting in Manchester. She has more than 15 years of experience in market access, predominantly as a consultant. Driven by a passion for addressing the challenges of high-cost, innovative treatments, she is committed to ensuring these therapies reach the right patients at the right time and price.To stay connected with...
2025-05-2024 min
MAP - Market Access PodcastHow Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?What does it take to succeed in Market Access? In this brand new episode of MAP, the Market Access podcast, Dr. Stefan Walzer sits down with industry veteran Adrian Kielhorn, co-author of The Market Access Guide. Together, they unpack the evolving role of market access professionals, the power of strategic thinking, mastering negotiations, and why patient centricity is key to success.Learn how to develop a strong value story, navigate pricing and reimbursement, and stay ahead in the dynamic pharmaceutical and healthcare landscape. Whether you’re a seasoned professional or just starting out, this episode is packed wi...
2025-05-1538 min
MAP - Market Access PodcastWhat Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing director at Red Thread, to break down the Joint Clinical Assessment (JCA) process, its impact on pharma, biotech, and medical device companies, and how early advice can shape market access and reimbursement strategies in Europe.Tune in to learn about JCA’s mandatory requirements, challenges, opportunities, and future developments as companies prepare for the evolving EU market access framework. JCA is changing the market access landscape in Europe - don’t mi...
2025-05-0135 min
tHEORetically SpeakingINsights & OUTcomes with Vernon SchabertWelcome to INsights & OUTcomes, the newest podcast on tHEORetically Speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.This episode features Dr. Vernon Schabert, Founder of Epilogix. Vernon is an internationally-recognized health economist and pharmacoepidemiologist and has nearly 30 years of HEOR, RWD, and RWE industry experience.To stay connected with us, visit our LinkedIn page and subscribe to our newsletter!Learn more about Epilogix: https://healtheconomics.com/suppliers/epilogix-llc/Health...
2025-04-2832 min
Progress, Potential, and Possibilities Podcast / ShowDr. Mirza Rahman, MD, MPH - President, American College of Preventive Medicine - The Power Of PreventionSend us a textDr. Mirza Rahman, MD, MPH serves as the President of the American College of Preventive Medicine ( ACPM - https://www.acpm.org/about-acpm/governance/executive-officers/mirza-rahman/ ), a professional community, founded in 1954 as a professional community for board-certified physicians to network, share their expertise and advocate for the advancement of prevention. Today, ACPM represents over 2,000 physicians, medical students, non-physicians, and other partners. All believe in the importance of preventive medicine in our society. Dr. Rahman also serves as the Senior Vice President, Patient Safety & Pharmacovigilance at Cybin ( https://cybin.com/our-team/ ), a p...
2025-04-261h 07
MAP - Market Access PodcastAre We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?Join the latest episode of the Market Access Podcast, where our host Dr. Stefan Walzer and expert Dr. Ahmed Seddik dissect the complexities of the societal impact of medical innovation. Dr. Ahmed Seddik shares important insights from his journey starting as a dentist in Egypt to his PhD research in health economics and social impact, focusing on how the access to innovation transforms communities and economies.Explore how medical innovation shapes healthcare systems and economies, and take part in the discussion of how health economics, cost-effectiveness, and societal impact influence reimbursement decisions. Listen now to learn more a...
2025-04-1533 min
tHEORetically SpeakingINsights & OUTcomes with Rosa WillockWelcome to INsights & OUTcomes, the newest podcast on tHEORetically Speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.This episode features Rosa Willock, a Senior Consultant at Decisive Consulting. She leads the RWE function at Decisive Consulting, which includes helping clients to identify and address gaps in their evidence packages, and more recently, helping them to plan for the new EUHTAR.To stay connected with us, visit our LinkedIn page and subscribe to our newsletter!
2025-03-3119 min
The Pulse of HealthcareUnderstanding U.S. Healthcare, Part IIIWhy do Americans pay substantially higher costs for prescriptions and medical care than other countries? Tune into Part 3 of the series on "Understanding US healthcare costs", as Dr. John and Peter explore the issues related to "Price Transparency" in the healthcare system. #HealthcareCosts #PriceTransparency #HealthcareReform #USHealthcare #HealthcarePolicy #HealthEconomics #EmployerBenefits #HealthcareInnovationLearn more about Ovation Health at www.ovation.health We help employers save up to 35% on their healthcare costs. For a free consultation call 866-549-4199 or email dr.john@ovation-health.com
2025-03-1926 min
No Ordinary SubjectsThe Plasma Paradox - The Ethics of Industry Profits & Donor CompensationThis episode of No Ordinary Subjects gets into the ethical complexities of the $24 billion plasma donation industry and the "Plasma Paradox": the vast financial gap between donor compensation and the multi-thousand dollar value of plasma-derived pharmaceuticals that come from each liter extracted. Examining the fairness of corporate profits versus donor payouts, also consider the long-term health effects of frequent plasma extraction. The episode covers the history of plasma use and life-saving therapies, financial disparities, and ethical concerns, and calls for more regulation, transparency, community investment, informed consent, and equitable compensation. There is credence in challenging the idea that altruism...
2025-03-1433 min
tHEORetically SpeakingINsights & OUTcomes with Chris O'NeillWelcome to INsights & OUTcomes, the newest podcast on tHEORetically speaking from HealthEconomics.com, where we sit down with the leading professionals in HEOR, RWE, and market access, the experts shaping the future of healthcare decisions.This episode features Chris O'Neill, founder and CEO of Bosun MA. He has has over 20 years’ experience developing and delivering value and Market Access solutions for Pharma clients at a global and regional level.BOSUN MA has over 20 years of expertise in payer understanding, and they use the latest AI technologies to help align clinical outcomes and Payer Ne...
2025-03-1031 min
tHEORetically SpeakingINsights & OUTcomes - COMING SOON to tHEORetically SpeakingJoin us for INsights & OUTcomes where we sit down with the leading professionals in HEOR, RWE & RWD, and Market Access, the experts shaping the future of healthcare decisions.We'll dive into their careers, their passions, and the biggest trends in health economics today. We break down the numbers, challenge assumptions, and uncover what really drives healthcare decision making.Subscribe now!
2025-02-2401 min
MIT Technology Review BrasilBiossimilares: a expansão das cópias de medicamentos biológicos 💊 #185Biossimilares: a expansão das cópias de medicamentos biológicos 💊 #185
Os biossimilares são a reprodução quase idêntica de medicamentos biológicos inovadores, produzidos após o vencimento de patentes. Regulamentados desde 2012 no país, esses produtos representam redução preços e uma consequente ampliação de acesso.
Países europeus têm políticas proativas que aceleraram a adoção dos biossimilares, garantindo maior acesso e economia. O Brasil, apesar de avanços regulatórios, ainda enfrenta desafios para a expansão dos produtos.
Neste podcast de Biotech and Health...
2024-12-2634 min
Empowered Patient PodcastIntegrating the Patient Perspective in Defining and Promoting Value-Based Healthcare with Rob Abbott ISPOR TRANSCRIPT Rob Abbott, CEO and Executive Director at ISPOR, the Professional Society for Health Economics and Outcomes Research, focuses on defining and measuring value in healthcare, including accessibility, affordability, effectiveness, and patient outcomes. HEOR (health economics and outcomes research) can provide data-driven insights to guide healthcare decision-making, reduce bias in research, and consider a broader range of factors like social determinants of health. This can improve treatment adherence, align therapies with what matters most to patients, and support the evaluation of technology used for treatments and predictive analysis of new therapies. Rob explains, "I'm excited at both the le...
2024-11-2500 minEmpowered Patient PodcastIntegrating the Patient Perspective in Defining and Promoting Value-Based Healthcare with Rob Abbott ISPOR Rob Abbott, CEO and Executive Director at ISPOR, the Professional Society for Health Economics and Outcomes Research, focuses on defining and measuring value in healthcare, including accessibility, affordability, effectiveness, and patient outcomes. HEOR (health economics and outcomes research) can provide data-driven insights to guide healthcare decision-making, reduce bias in research, and consider a broader range of factors like social determinants of health. This can improve treatment adherence, align therapies with what matters most to patients, and support the evaluation of technology used for treatments and predictive analysis of new therapies. Rob explains, "I'm excited at both the le...
2024-11-2517 min
tHEORetically SpeakingtHEORetically speaking: Making Real-World Data Research-ReadyThis episode of tHEORetically Speaking features Jeffrey Brown, PhD and Matvey Palchuk, MD, MS, FAMIA of TriNetX, who discuss the rise of RWD and its role in revolutionizing healthcare research, and how the TriNetX team approaches data quality to ensure research-ready RWD.With increasing use of real-world data (RWD) throughout the drug development cycle — from initial discovery through to market approval and post-market monitoring — comes increasing scrutiny about the quality of the data. To watch the full interview, click here.
2024-11-0723 min
Delta: HealthTech InnovatorsFrom Fee-for-Service to Value-Based Care: The Evolution of Healthcare Payment ModelsIn this episode, we dive deep into the fascinating journey of healthcare payment models and how they're transforming to enhance patient care, reduce costs, and improve the well-being of healthcare providers.What You'll Learn:The Traditional Fee-for-Service Model: Understand how paying for each individual service led to a focus on quantity over quality.The Rise of HMOs in the 1970s: Explore how Health Maintenance Organizations aimed to control costs and emphasize preventive care.Introduction of DRGs in the 1980s: Discover how Diagnosis-Related Groups incentivized hospitals to improve efficiency.Standardizing...
2024-10-1617 min
tHEORetically SpeakingtHEORetically speaking: Between Two Scientists: Care During Pregnancy - How RWD Can Help Balance the Needs of Mom and BabyThis episode of tHEORetically Speaking is the fourth podcast in Panalgo’s ‘Between Two Scientists’, featuring host Meg Richards, PhD, MPH, who sits down with Panalgo’s VP of Medical Affairs, Dr. Mark Friedman, to discuss balancing the health needs of a pregnant woman and her developing baby, and how RWD can help.Have a listen to the third ‘Between Two Scientists’ podcast, where Norstella’s General Manager of RWD, Ted Search, highlighted the challenges of incorporating new types of unstructured real-world data with structured data.For more information or to access other resources, cli
2024-09-2412 min
The Agency AdvantageUnlocking the Secrets of Health Economics with Abi StevensonSend us a textIn this exciting episode of The Agency Advantage, join me as I welcome the insightful Abi Stevenson to discuss her role in Health Economics and Outcomes Research (HEOR). Abi, a Senior Manager at Chiesi Rare Disease, shares her fascinating journey from a med comms agency to the pharma sector, emphasizing the value of hands-on experience over formal qualifications. Learn about the crucial function of HEOR in demonstrating the economic value of high-cost therapies, especially in rare diseases, and discover practical advice on breaking into this field. If you're considering a career in HEOR...
2024-08-0719 minProgress, Potential, and Possibilities Podcast / ShowDr. William Padula, PhD - Assistant Professor, Pharmaceutical & Health Economics and Fellow, Schaeffer Center for Health Policy & Economics, Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences, USC - Assessing Healthcare Value To Improve OutcomesSend us a textDr. William Padula, PhD, MS, MSc, is Assistant Professor, Pharmaceutical & Health Economics and Fellow, Schaeffer Center for Health Policy & Economics, at the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences, University of Southern California ( https://healthpolicy.usc.edu/author/william-padula-phd/ ). His research explores the theoretical foundations of medical cost-effectiveness analysis, especially pertaining to issues around the value of vaccines, healthcare delivery and patient safety in hospitals for acquired conditions such as pressure injuries. He has received grant funding in the form of a Career Development Award from the National Institutes of Health (NIH...
2024-07-0957 min
tHEORetically SpeakingtHEORetically speaking: How AI-Powered Phenotyping Enhances the Patient Journey for Life Science ApplicationsIn this episode of tHEORetically speaking, Dr. Joseph Zabinksi, VP and Head of Commercial Strategy and AI at OM1, explains how AI-powered digital phenotyping can enhance our understanding of patients' experiences and inform access, treatment, and condition management.Real-world data provides an opportunity to understand what happens to patients, but there are limitations to the insights we can generate using traditional analysis techniques alone. At OM1, our PhenOM technology uses AI to isolate subtle signals in real-world data associated with outcomes we care about - diagnoses, treatment response, and future risks. The insights we derive...
2024-04-2514 min
tHEORetically SpeakingtHEORetically speaking: Clinical Outcomes Assessments and TrainingIn this episode of tHEORetically Speaking, join Kelly Lipman, Heather Dickerson, and Ryan Murphy from ICON, who answer questions from a recent webinar on the dynamic landscape of clinical outcomes assessments, examining their historical significance, current uses and best practices, and making a case for greater standardization in their implementation.For more information, to watch the webinar, or access other resources, click here.
2024-03-1408 min
tHEORetically SpeakingtHEORetically speaking: EU HTA Joint Clinical AssessmentsIn this episode of tHEORetically Speaking, join Dr. Rosemary Jose, Dr. Sonja Kroep, and Nick Halfpenny from OPEN Health, Dr. Ansgar Hebborn from Roche, and James Ryan from AstraZeneca, who answer questions from a recent webinar on several policy aspects regarding the current challenges and implications of the EU Health Technology Assessment (HTA) regulation.For more information, to watch the webinar, or access other resources, click here.
2024-03-1413 min
tHEORetically SpeakingtHEORetically speaking: Cell & Gene TherapiesIn this episode of tHEORetically Speaking, join Dr. Pamela Landsman-Blumberg, Amanda O’Hora, and Ajay Keshava from Magnolia Market Access, who answer questions from a recent webinar on how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.For more information, to watch the webinar, or access other resources, click here.
2024-03-1405 min
tHEORetically SpeakingtHEORetically speaking: Patient-Centered Real-World Evidence in Rare DiseasesIn this episode of tHEORetically Speaking, join Drs. Megan Gower and Edward Chou from Takeda, and Richard Tsai, MS from Inspire, who answer questions from a recent webinar on the challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases, to support clinical development through commercial post-approval.For more information, to watch the webinar, or access other resources, click here.
2024-03-1315 min
tHEORetically SpeakingtHEORetically speaking: Real-World Evidence Generation with Disease RegistriesIn this episode of tHEORetically Speaking, join Drs. Javier Cid, Nahila Justo, and Delphine Saragoussi from Evidera and PPD, who answer questions from a recent webinar on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.For more information, to watch the webinar, or access other resources, click here.
2024-03-1104 min
tHEORetically SpeakingtHEORetically speaking: Clinical Outcome Assessment (COA) TranslationsIn this episode of tHEORetically speaking, join Christelle Giroudet, MA and Ana Alvarez, MA, COA Linguistic Validation Leaders with ICON, as they highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.For more information, to watch the webinar, or access other resources, click here.
2024-03-1122 min
tHEORetically SpeakingtHEORetically speaking: Between Two Scientists - New Types of DataThis episode of tHEORetically Speaking is the third installment of Panalgo’s ‘Between Two Scientists’, featuring host Meg Richards, Executive Director of Solutions at Panalgo, who chats with Norstella’s General Manager of RWD, Ted Search, General Manager of RWD at Norstella about new types of unstructured real-world data and the challenges of incorporating them with structured data.Have a listen to the second ‘Between Two Scientists’ podcast which covered the privacy certification of linked data with Bobby Samuels of Datavant.For more information or to access other resources, click here.
2024-03-0407 min
tHEORetically SpeakingtHEORetically speaking: Total System Value™ - A DYNAMIC APPROACH TO VALUE DEMONSTRATIONHEOR Ltd. have been working on an exciting new framework called Total System Value™. This episode of tHEORetically speaking features their CEO Phil McEwan and CGO Jeff Anderson to talk to us about this dynamic approach to value demonstration. Total System Value™ (TSV)™ is a new, dynamic framework designed to assess the value of adopting a new technology or policy initiative at a population level. For more information or to access other resources, click here.
2024-01-0822 min
tHEORetically SpeakingtHEORetically speaking: Between Two Scientists - Labeling and Certifying your Varietal Data BlendThis episode of tHEORetically Speaking is the second installment of Panalgo's 'Between Two Scientists', featuring host Meg Richards, Executive Director of Solutions at Panalgo, and Bobby Samuels, General Manager of Privacy Hub at Datavant.In the first episode of ‘Between Two Scientists', we talked about data linkages and the need to certify the linked data before they can be used for research. In this episode, we’re picking up the data certification thread. Like the first episode, this one is also to wine-making.For more information or to access other resources, clic...
2023-11-2908 min
tHEORetically SpeakingtHEORetically speaking: How AI Can Help Dermatology: Diagnosis, Treatment, Risk, and R&DThe hype around AI is finally translating into real-world value, and we are seeing broader adoption of real-world data in Dermatology. This episode of tHEORetically Speaking features Dr. Stefan Weiss, Managing Director of Dermatology and Dr. Joseph Zabinski, Managing Director of AI and Personalized Medicine at OM1, who discuss the path to personalized medicine and AI-powered clinical decision support in dermatology.For more information or to access other resources, click here.
2023-11-1515 min
Chai with Ping | Immigrants | Cross-Cultures[International Student] Ep96 Doc Student from Chennai to Colorado w/ SnehaSneha was on the show in 2020, and let's hear her stories after coming to the U.S. Being a doc student from India in Colorado, what challenges does she face, and what comforts does she find? Find her on IG @acehibiscusinfinity https://www.instagram.com/acehibiscusinfinity or sneha.srinivasan4444@gmail.com Sneha's previous episode: Ep35 Study In Taiwan and I found Healing 📝Episode Outline (00:00) Intro & Health Economics (09:21) Life in Colorado/Cold/Exam Styles/Funding/Coping (21:31) Enjoyment/Stereotypes/Hai...
2023-10-3035 min
tHEORetically SpeakingtHEORetically speaking: The Future of Diversity in Clinical Trials: Real-World EvidenceThis episode of tHEORetically Speaking features real-world evidence experts Alexandrina Balanean, Parisa Asgarisabet, and Danielle Gentile from Cardinal Health discussing the problems caused by lack of diverse representation in clinical trials.The underrepresentation of disproportionately burdened groups limits information on therapeutic response, safety, and efficacy to a small subset of the population—which tends to be healthier, more well-educated, and financially advantaged. However, recent findings show that real-world evidence (RWE) may be able to help with this underrepresentation. Listen in to learn more about these findings and what it may mean for the fu...
2023-10-3008 min
tHEORetically SpeakingtHEORetically speaking: Between Two Scientists - Data LinkageThis episode of tHEORetically Speaking features our host Meg Richards, Executive Director of Solutions at Panalgo, who will be speaking with Erik Maul, Senior Director of Data Partnerships at Panalgo about data linkage.The healthcare and life sciences industries are currently experiencing transformative times of growth. The explosion of real-world data, new regulatory programs and frameworks, and a focus on AI and machine learning are only a few of the factors contributing to this rapidly evolving landscape. In this podcast – we’re aiming to illuminate these catalysts of change by talking to the experts themselves. From...
2023-09-2707 min
tHEORetically SpeakingtHEORetically speaking: Detecting and Decoding Alzheimer's with Real-World DataThe landscape for Alzheimer's disease is rapidly changing. This episode of tHEORetically speaking features Dr. Carl Marci from OM1 and Dr. Luke Stoeckel from NIA, as they discuss the critical need for earlier detection leading to potentially life changing earlier interventions.For more information or to access other resources, click here.
2023-09-2016 min
tHEORetically SpeakingtHEORetically speaking: Leveraging Real-World Data for Precision Obesity TreatmentIn this episode of tHEORetically speaking, Gary Curhan, Chief Medical Officer and Jessica Paulus, Vice President of Research at OM1, as they answer questions on Leveraging Real-World Data for Precision Obesity Treatment. For more information or access other resources, click here.
2023-07-2625 min
tHEORetically SpeakingtHEORetically speaking: Medicare and Medicaid Services Market PricingIn this episode of tHEORetically Speaking, join ICON experts Mark McCoy, Dr. Earlene Biggs, Bruce Capobianco, Dr. Tanja Obradovic, Ki Park, and Nancy Risebroughas they answer questions on the Centers for Medicare and Medicaid Services’ negotiations on the fair market prices for Medicare Part D products.For more information, to watch the webinar, or access other resources, click here.
2023-07-0605 min
tHEORetically SpeakingtHEORetically speaking: Medicare Data for RWD AnalysisIn this episode of tHEORetically Speaking, join Dr. Eunice Chang and Dr. Michael Broder from PHAR, and Mitra Corral from Genentechas they answer questions on the how and why use of Medicare data for conducting various types of RWD analysis is important.For more information, to watch the webinar, or access other resources, click here.
2023-07-0411 min
Dementia ResearcherInside the Global Brain Health InstituteIn this podcast we explore the world of brain health and the Atlantic Fellows for Equity in Brain Health program of the Global Brain Health Institute (GBHI), from Trinity College Dublin and University of California San Francisco.
Join us as we speak with world-class faculty members and fellows about their experiences in this cutting-edge program that's changing the face of brain health leadership and creating new attitudes. From neuroscience to psychology, public health to neurology, and even the arts and communications we'll take you on a journey through the amazing work being done by the Global Brain Health Institute. Tune...
2023-05-2247 min
tHEORetically SpeakingtHEORetically speaking: The Benefits of Linking SDOH Data with Other Real-World DataIn this episode of tHEORetically speaking, join Dr. Pamela Landsman-Blumberg from Magnolia Market Access and Dr. Rick Chapman from Innovation and Value Initiativeas they answer questions on the importance of social determinants of health (SDOH) and describe the benefits of linking SDOH data with other real-world data when conducting health economics and outcomes research (HEOR).For more information, to watch the webinar, or access other resources, click here.
2023-05-1104 min
tHEORetically SpeakingtHEORetically speaking: Improving the Representativeness of ResearchIn this episode of tHEORetically speaking, join Dr. Bruce Feinberg, Dr. Danielle Gentile, Dr. Parisa Asgarisabet, and Alexandrina Balanean from Cardinal Health as they answer questions on the economic impact and role of real world evidence (RWE) in improving representativeness of research.For more information, to watch the webinar, or access other resources, click here.
2023-04-1207 min
tHEORetically SpeakingtHEORetically speaking: Literature Reviews and Global Value DossiersIn this episode of tHEORetically speaking, join Gillian Sibbring, Sue O’Leary, Ben Rousseau, Patti Peeples, and Rachel Forrest as they answer questions on systematic literature review issues that can negatively affect your Global Value Dossiers (GVDs) and how automation can improve your product's market access.For more information, to watch the webinar, or access other resources, click here.
2023-04-0510 min
tHEORetically SpeakingtHEORetically speaking: Causal Inference In Real-World Healthcare DataIn this episode of tHEORetically Speaking, join Michael Grabner, Alexander Turchin, and Shivani Pandya as they answer questions on causal inference and designing these studies using real-world healthcare data.
2023-02-0710 min
tHEORetically SpeakingtHEORetically speaking: Health Economics and Outcome Research for Medical TechnologyIn this episode of tHEORetically Speaking, join Deepak Sahu as he answers questions on developing Health Economics and Outcomes Research (HEOR) studies for generating short- and long-term effectiveness data for medical technology.
2023-02-0715 min
tHEORetically SpeakingtHEORetically speaking: Exploring Social Media Data in Different ContextsIn this episode of tHEORetically speaking, join Elodie de Bock, Valentin Barbier, Adel Mebarki, and Joelle Malaab as they answer questions on how to collect, use, analyze, and interpret social media data in different contexts.
2022-12-1212 min
tHEORetically SpeakingtHEORetically speaking: Discussing Health Technology Assessment AgenciesIn this episode of tHEORetically speaking, join Chris Waters-Banker, Maria Arregui, Rajshree Pandey, Lee-Anne Bourke, and Patti Peeples as they answer questions on what Health Technology Assessment (HTA) agencies do and the types of literature reviews they do.
2022-12-0908 min
tHEORetically SpeakingtHEOretically speaking: Platforms and Models for Payer Insights and Evidence GenerationIn this episode of tHEORetically speaking, join Priti Jhingran and Tijana Ignjatovic as they answer questions on opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.
2022-12-0808 min
tHEORetically SpeakingtHEORetically speaking: Delphi panelsIn this episode of tHEORetically Speaking, join Jincy Paulose, George Joseph, and Michael Broder as they answer questions around leading Delphi panels, their experience participating in the discussions, and how they have used the results.
2022-12-0511 min
tHEORetically SpeakingtHEORetically speaking: Improving Health LiteracyIn this episode of tHEORetically Speaking, join Danielle Drachmann, Josie Godfrey, Kristine Sorensen, Beth Lesher, Kelly McCarrier, and Gavin Jones as they answer questions on how to improve health literacy and the understandability of the HEOR process to enable effective partnerships, as well as to assist patients to participate in shared decision making with their physicians.
2022-11-2915 min
tHEORetically SpeakingtHEORetically speaking: Infectious Disease ModelingIn this episode of tHEORetically Speaking, join Marija Zivkovic-Gojovic, Richard Pitman, and Pragya Khurana as they answer questions on infectious disease modeling, the assessment of interventions, and the challenges around these analyses.
2022-11-2214 min
tHEORetically SpeakingtHEORetically speaking: Getting Real About Real-World DataIn this episode of tHEORetically speaking, Bill Saunders from IntegraConnect discusses Real-World Data and Real-World Evidence in the context of value-based care and precision medicine for specialty care.To read the full blog and watch the interview click here.
2022-11-1713 min
tHEORetically SpeakingtHEORetically speaking: Utilizing RWD, Machine Learning, and System BiologyIn this episode of tHEORetically Speaking, join Nitin Baliga, Insitute for Systems Biology, and Thomas Brown, Syapse as they answer questions on utilizing real-world data, machine learning, and systems biology for benefiting therapeutic development.
2022-10-2707 min
tHEORetically SpeakingtHEORetically speaking: How Accelerated Drug Development Requires Disruption in Market Access and Pricing We recently sat down with Preeti Patel, MPharm, CEO and Founder of GPI, to learn what is driving the growing importance for early stage asset value and price prediction, how GPI is supporting clients through these challenges, and how this solution was developed.Global Pricing Innovations (GPI) is a price and access insights company that uses analytics to provide data-driven, evidence-based support, and helps clients make better investment decisions for drug development and commercialization. Read the full blog post here.
2022-10-1308 min
tHEORetically SpeakingtHEORetically speaking: Evidence Generation PlanningIn this episode of tHEORetically speaking, join Colin Oliver, Anila Dede, Erwin De Cock, and Arshi Gupta from Syneos Health as they answer questions on evidence generation planning for clinical and commercial success and improvement of patient outcomes.
2022-08-1811 min
tHEORetically SpeakingtHEORetically speaking: Renee Willmon on Health StorylinesIn this episode of tHEORetically speaking, join Renee Willmon as she answers questions on Health Storylines, a disease-agnostic and customizable platform that connects healthcare stakeholders to engaged patients.
2022-07-1520 min
tHEORetically SpeakingtHEORetically speaking: Information for Healthcare Decision-MakersIn this episode of tHEORetically speaking, join Earlene Biggs, Gary Owens, and Renee Fleming, as they answer questions regarding information sharing with healthcare decision-makers for optimized engagement.
2022-07-1202 min
tHEORetically SpeakingtHEORetically speaking: Embracing FDA Guidance on Real World DataIn this episode of tHEORetically speaking, join Raina Olexa and Mui Van Zandt as they answer questions on embracing FDA’s guidance on the use of real world data (RWD) to understand how your organization can navigate data quality, curation, and management challenges for better research.
2022-06-2303 min
tHEORetically SpeakingtHEORetically speaking: Algorithms for Real World EvidenceIn this episode of tHEORetically Speaking, join Eric Benchimol, Karina Raimundo, Anil Vachani, and Michael Broder as they answer questions on validation of code algorithms for Real World Evidence (RWE).
2022-06-2114 min
tHEORetically SpeakingtHEORetically speaking: Real-World Evidence and Neonatal OutcomesIn this episode of tHEORetically Speaking, join Eric Stanek, Michael Grabner, Deb Discenza, Jennifer Degl, and Thomas Miller as they answer questions on improving neonatal outcomes using Real World Evidence (RWE).To learn more, click here.
2022-06-1608 min
tHEORetically SpeakingtHEORetically speaking: Literature Review AutomationIn this episode of tHEORetically speaking, join Shirley Sylvester, Vardhini Ganesh, Richa Goyal Rai, and Lee-Anne Bourke as they answer questions where they discuss how literature review automation helps solve the daily challenges facing research professionals.To learn more click here.
2022-05-3013 min
Ars BoniArs Boni Episode 111 - Mental And Public Health (Prof. Judit Simon)In this episode we are talking to Prof. Judit Simon, who is a professor of Health Economics at the Medical University of Vienna. We talk about Public Health in general and the effects of Covid-19 on mental health in particular.
Link: https://healtheconomics.meduniwien.ac.at/general-information/team/judit-simon/
2021-01-2757 min
Well-Oiled Operations with Stacy Tuschl#94: You Don't Need Employees to Delegate, with Amy SmalarzAmy Smalarz is a woman, wife, mother, and daughter who for many years struggled with trying to live up to what she perceived as everyone else's expectations of her and lost herself in the process. As an entrepreneur and business owner, she works and collaborates with people to help them realize they are not alone, to celebrate their road traveled (celebrate YOU for being YOU) and to map out their next destination in life (personal and professional). Amy is a lifelong student. She has earned degrees in Biology and Sociology; a Masters in Healthcare Administration; and a...
2016-09-1424 min
Relentless Health ValueEpisode 17: The History of Health Economics with Patti Peeples from HealthEconomics.com Dr. Patti Peeples is a health economist, pharmaceutical marketer, pharmacist, and entrepreneur with 25 years of experience in the pharma industry. She is Founder and CEO of HealthEconomics.Com, a top-ranked resource portal that serves as the global pharmaceutical and payer industry's CONNECTED COMMUNITYTM for individuals involved in establishing value for healthcare interventions, including those in the health economics, outcomes research, pricing, reimbursement, and market access. Dr. Peeples has served in senior positions in Medical Affairs, Health Outcomes, and Product Management and has worked for major pharma and device organizations including ALZA, Sandoz (now Novartis), and Xcenda. She...
2014-10-1645 min